In April 2021, Charles River acquired Cognate BioServices, which included Cobra Biologics, a leading international contract development and manufacturing organization (CDMO) specializing in premium plasmid DNA and viral vector services to support the Advanced Therapy Medicinal Products (ATMP) industry. Cobra and Cognate, alongside Vigene Biosciences, join Charles River to offer customers a single, trusted partner. We have since supported the development of 15 FDA-approved cell and gene therapies and have conducted more than 1,000 studies in this field over the past year.
%20-%20Block%2050%20(2).jpg?crop=true&keep=c&q=80&color=ffffffff&u=atq9fr&w=640&h=426)
Accelerate the development of your product and ensure it meets the highest regulatory standards while maintaining efficient production timelines through our integrated global network of contract development and manufacturing organization (CDMO) facilities and testing sites.
Still have questions for our cell and gene therapy specialists?
Connect With Us